Drugs / Piromelatine
Piromelatine
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01114126 | Apr 2010 → Feb 2011 | insomnia | Neurim Pharmaceuticals Ltd. | Completed | No outcome recorded |
| Phase 21 trial · 1 missed | ||||||
| Phase 2 | NCT02615002 | Nov 2015 → Jun 2019 | Alzheimer disease | Neurim Pharmaceuticals Ltd. | Completed | Missed primary |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT05267535 | May 2022 → Jun 2025 overdue | Alzheimer disease | Neurim Pharmaceuticals Ltd. | Active not recruiting | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT01489969 Comparator | Dec 2011 → May 2012 | insomnia | Neurim Pharmaceuticals Ltd. | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Piromelatine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05267535 ↗ |
| Known as | Neu-P11 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01114126 ↗ |
| Known as | Piromelatina | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297523 ↗ |
| Action | Activate | “Melatonin agonist” NCT01489969 ↗ |
| Modality | Small molecule | — CHEMBL4297523 ↗ |
| Route | Oral | “orally administered Neu-P11” NCT01114126 ↗ |